Previous 10 | Next 10 |
2024-04-11 05:46:53 ET Novartis ( NYSE: NVS ) has commenced its tender offer to acquire all outstanding shares of German cancer drugmaker MorphoSys ( NASDAQ: MOR ) for an offer price of EUR 68 a share or €2.7B aggregate in cash.... Read the full article on S...
2024-04-10 06:50:33 ET Summary Halozyme's ENHANZE technology drives growth, with Q4 2023 revenue up 27% YoY, projecting $915-$985 million in 2024. Key revenue from royalties, notably Darzalex Faspro, with a healthy financial state highlighted by a strong current ratio and stock re...
2024-04-09 14:53:06 ET More on STOXX Europe 600 Index: U.S. Employment Data To Set Dollar's Course Greenback Losses Extended, But Look For Consolidation In North America Rate Adjustment Underpins Greenback JPMorgan’s top European picks European...
2024-04-07 13:31:00 ET More on Merck, SPDR S&P Biotech ETF, etc. Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade) Merck: Better Times Ahead On Approvals And Outlook Merck's Future Brightens With Winrevair's Blockbuster Potential ...
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting PR Newswire V- INITIATE trial demonstrates that early initiation with Leqvio,...
2024-04-06 09:26:54 ET More on Amneal, Bausch Health, etc. Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Bausch Health: A Timely Divestiture Is The Key To An Higher Val...
Novartis AG (NYSE: NVS) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 3.29% on the day to $97.47. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through ...
2024-04-04 00:56:46 ET Summary Novartis is now a pure player in innovative medicines. Despite a negative FX, the company reported solid 2023 financial results and increased its dividend per share. There is a strategic rationale for acquiring MorphoSys AG. NVS had raised its ou...
2024-04-02 15:38:04 ET More on Intra-Cellular Therapies Intra-Cellular Therapies Is On Fire Intra-Cellular Therapies, Inc. (ITCI) Q4 2023 Earnings Call Transcript Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy' I...
2024-04-02 11:36:00 ET More on CRISPR Therapeutics Crispr Therapeutics: I'm Not Betting Against Gene Editing This Time (Upgrade) Crispr Therapeutics: Cautiously Optimistic CRISPR Therapeutics AG (CRSP) Presents at Citi 2024 Virtual Oncology Leadership Summit Conferen...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...